Work

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Year: 2013

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(12)62190-4

Authors: Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Xavier Montalban, Ernst-Wilhelm Radue, Dusan Stefoski, Randy Robinson, Katherine Riester, Jitesh Rana, Jacob Elkins, Gilmore O'Neill

Institutions: St. Josef-Hospital, Ruhr University Bochum, Queen Mary University of London, Blizard Institute, Medical University of Lodz, Charles University, Vall d'Hebron Hospital Universitari, University Hospital of Basel, Rush University Medical Center, AbbVie Biotherapeutics (United States), Biogen (United States)

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Biogen, AbbVie, Ministerstvo Školství, Mládeže a Tělovýchovy, IC Design Education Center, AbbVie Biotherapeutics

Awards: G366362906, G4745113146

OpenAlex ID: W2167414238

FWCI: 29.45

Cites: 30

Cited by: 291

Related to: 10